Questions to ask the study team

- Why do researchers believe the study drug may work?
- How long will I or my loved one be on the study drug?
- What are the chances of receiving a placebo (inactive substance)?
- What were results of previous studies in which the study drug was used?
- How does the study drug differ from standard medications to control behavior associated with Alzheimer's disease?
- Are there foods, prescriptions, over-the- counter medications or activities that should be avoided while taking the study drug?
- What tests will be performed?
- What do you expect to learn from these tests?
- How and when will I know the results of the tests?

For more information or to find a clinic near you visit:

www.citadtrial.org

or contact

Parkwood Institute Mental Health Building
550 Wellington Road, London, ON
Contact: Dr. Amer Burhan
Phone: (519) 646-6100 x 48170
Email: amer.burhan@sjhc.london.on.ca

JOHNS HOPKINS MEDICINE

NIH National Institute on Aging

Do you or a loved one experience

AGITATION

with Alzheimer's disease?

Find out more about participating in the

S-CitAD Research Study

Sudden outbursts of anger, aggression or agitation can be part of Alzheimer's disease progression. Managing these symptoms can be difficult. But, you're not alone! Doctors are working daily to find treatments.

The Escitalopram for Agitation in Alzheimer's Disease study is being conducted to determine if a study drug given as a pill can safely and effectively reduce the symptoms of agitation and aggression in people with Alzheimer's disease.

Individuals may be eligible for this study if they:

- Have a diagnosis of Alzheimer's disease
- Experience frequent agitation or aggression
- Have a caregiver who spends at least several hours per week with him/her and supervises his/her care, is willing to accompany the participant to study visits, and is willing to participate in the study
- Are available for 6 months of follow-up

About the study

The study will last approximately 6 months and will include 6 clinic study visits and 7 telephone contact visits. Participants will be randomized to receive either the study drug (escitalopram) or a placebo (inactive substance) for the first 12 weeks. Following the 12-week study treatment period, participants will be followed for another 12 weeks without receiving any study drug.

All participants and caregivers will receive counseling and materials to help manage agitation.

About the study drug

Escitalopram is widely used in patients. It will be administered orally in pill form. As with any medication, the study drug may cause side effects. There is also no guarantee the study drug will be effective. The study doctor will explain all potential risks and benefits during your first visit, before you decide whether you want to participate in the study.

Protecting study participants

There are strict laws governing the conduct of clinical studies. A process called informed consent ensures you know all the facts regarding study participation prior to enrolling in the study. If you decide to participate, you or your loved one will sign an informed consent document. This document is not a contract, and you may withdraw from the study at any time. If you decide to withdraw, you will undergo another safety assessment as part of the continuous safety monitoring provided throughout the study.

All participants will be monitored throughout the study, and a team will be on hand to answer all questions related to the study.

The study drug and study-related procedures will be provided at no cost. Cost of travel related to the study may be reimbursed.